The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Companion Diagnostic-Global Market Insights and Sales Trends 2024
Synopsis
A companion diagnostic device is a special type of invitro medical device that provides information, which is necessary for the effective and safe use of an analogous drug or biological product. Companion diagnostics are developed simultaneously with drugs to help include or exclude a certain group of patients for treatment with a particular drug based on their biological characteristics, which determines patients who respond and those who dont respond to the therapy.
The global Companion Diagnostic market size is expected to reach US$ 32340 million by 2029, growing at a CAGR of 20.3% from 2023 to 2029. The market is mainly driven by the significant applications of Companion Diagnostic in various end use industries. The expanding demands from the Oncology, Cardiovascular, Central Nervous System and Virology, are propelling Companion Diagnostic market. Immunohistochemistry, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Molecular Diagnosis segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Companion Diagnostic, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Companion Diagnostic market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Companion Diagnostic market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Companion Diagnostic sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Companion Diagnostic covered in this report include Roche Holdings, Abbott Laboratories, Thermo Fisher Scientific, Agilent Technologies, Merck, Agendia, Qiagen, Myriad Genetics and Advanced Cell Diagnostics, etc.
The global Companion Diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Holdings
Abbott Laboratories
Thermo Fisher Scientific
Agilent Technologies
Merck
Agendia
Qiagen
Myriad Genetics
Advanced Cell Diagnostics
Danaher
Illumina, Inc
Global Companion Diagnostic market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Companion Diagnostic market, Segment by Type:
Immunohistochemistry
Molecular Diagnosis
Global Companion Diagnostic market, by Application
Oncology
Cardiovascular
Central Nervous System
Virology
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Companion Diagnostic companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
A companion diagnostic device is a special type of invitro medical device that provides information, which is necessary for the effective and safe use of an analogous drug or biological product. Companion diagnostics are developed simultaneously with drugs to help include or exclude a certain group of patients for treatment with a particular drug based on their biological characteristics, which determines patients who respond and those who dont respond to the therapy.
The global Companion Diagnostic market size is expected to reach US$ 32340 million by 2029, growing at a CAGR of 20.3% from 2023 to 2029. The market is mainly driven by the significant applications of Companion Diagnostic in various end use industries. The expanding demands from the Oncology, Cardiovascular, Central Nervous System and Virology, are propelling Companion Diagnostic market. Immunohistochemistry, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Molecular Diagnosis segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Companion Diagnostic, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Companion Diagnostic market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Companion Diagnostic market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Companion Diagnostic sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Companion Diagnostic covered in this report include Roche Holdings, Abbott Laboratories, Thermo Fisher Scientific, Agilent Technologies, Merck, Agendia, Qiagen, Myriad Genetics and Advanced Cell Diagnostics, etc.
The global Companion Diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Holdings
Abbott Laboratories
Thermo Fisher Scientific
Agilent Technologies
Merck
Agendia
Qiagen
Myriad Genetics
Advanced Cell Diagnostics
Danaher
Illumina, Inc
Global Companion Diagnostic market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Companion Diagnostic market, Segment by Type:
Immunohistochemistry
Molecular Diagnosis
Global Companion Diagnostic market, by Application
Oncology
Cardiovascular
Central Nervous System
Virology
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Companion Diagnostic companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Companion Diagnostic
1.1 Companion Diagnostic Market Overview
1.1.1 Companion Diagnostic Product Scope
1.1.2 Companion Diagnostic Market Status and Outlook
1.2 Global Companion Diagnostic Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Companion Diagnostic Market Size by Region (2018-2029)
1.4 Global Companion Diagnostic Historic Market Size by Region (2018-2023)
1.5 Global Companion Diagnostic Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Companion Diagnostic Market Size (2018-2029)
1.6.1 North America Companion Diagnostic Market Size (2018-2029)
1.6.2 Europe Companion Diagnostic Market Size (2018-2029)
1.6.3 Asia-Pacific Companion Diagnostic Market Size (2018-2029)
1.6.4 Latin America Companion Diagnostic Market Size (2018-2029)
1.6.5 Middle East & Africa Companion Diagnostic Market Size (2018-2029)
2 Companion Diagnostic Market by Type
2.1 Introduction
2.1.1 Immunohistochemistry
2.1.2 Molecular Diagnosis
2.2 Global Companion Diagnostic Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Companion Diagnostic Historic Market Size by Type (2018-2023)
2.2.2 Global Companion Diagnostic Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Companion Diagnostic Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Companion Diagnostic Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Companion Diagnostic Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Companion Diagnostic Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Companion Diagnostic Revenue Breakdown by Type (2018-2029)
3 Companion Diagnostic Market Overview by Application
3.1 Introduction
3.1.1 Oncology
3.1.2 Cardiovascular
3.1.3 Central Nervous System
3.1.4 Virology
3.1.5 Others
3.2 Global Companion Diagnostic Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Companion Diagnostic Historic Market Size by Application (2018-2023)
3.2.2 Global Companion Diagnostic Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Companion Diagnostic Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Companion Diagnostic Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Companion Diagnostic Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Companion Diagnostic Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Companion Diagnostic Revenue Breakdown by Application (2018-2029)
4 Companion Diagnostic Competition Analysis by Players
4.1 Global Companion Diagnostic Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Companion Diagnostic as of 2022)
4.3 Date of Key Players Enter into Companion Diagnostic Market
4.4 Global Top Players Companion Diagnostic Headquarters and Area Served
4.5 Key Players Companion Diagnostic Product Solution and Service
4.6 Competitive Status
4.6.1 Companion Diagnostic Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche Holdings
5.1.1 Roche Holdings Profile
5.1.2 Roche Holdings Main Business
5.1.3 Roche Holdings Companion Diagnostic Products, Services and Solutions
5.1.4 Roche Holdings Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Holdings Recent Developments
5.2 Abbott Laboratories
5.2.1 Abbott Laboratories Profile
5.2.2 Abbott Laboratories Main Business
5.2.3 Abbott Laboratories Companion Diagnostic Products, Services and Solutions
5.2.4 Abbott Laboratories Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.2.5 Abbott Laboratories Recent Developments
5.3 Thermo Fisher Scientific
5.3.1 Thermo Fisher Scientific Profile
5.3.2 Thermo Fisher Scientific Main Business
5.3.3 Thermo Fisher Scientific Companion Diagnostic Products, Services and Solutions
5.3.4 Thermo Fisher Scientific Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.3.5 Agilent Technologies Recent Developments
5.4 Agilent Technologies
5.4.1 Agilent Technologies Profile
5.4.2 Agilent Technologies Main Business
5.4.3 Agilent Technologies Companion Diagnostic Products, Services and Solutions
5.4.4 Agilent Technologies Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.4.5 Agilent Technologies Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Companion Diagnostic Products, Services and Solutions
5.5.4 Merck Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Agendia
5.6.1 Agendia Profile
5.6.2 Agendia Main Business
5.6.3 Agendia Companion Diagnostic Products, Services and Solutions
5.6.4 Agendia Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.6.5 Agendia Recent Developments
5.7 Qiagen
5.7.1 Qiagen Profile
5.7.2 Qiagen Main Business
5.7.3 Qiagen Companion Diagnostic Products, Services and Solutions
5.7.4 Qiagen Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.7.5 Qiagen Recent Developments
5.8 Myriad Genetics
5.8.1 Myriad Genetics Profile
5.8.2 Myriad Genetics Main Business
5.8.3 Myriad Genetics Companion Diagnostic Products, Services and Solutions
5.8.4 Myriad Genetics Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.8.5 Myriad Genetics Recent Developments
5.9 Advanced Cell Diagnostics
5.9.1 Advanced Cell Diagnostics Profile
5.9.2 Advanced Cell Diagnostics Main Business
5.9.3 Advanced Cell Diagnostics Companion Diagnostic Products, Services and Solutions
5.9.4 Advanced Cell Diagnostics Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.9.5 Advanced Cell Diagnostics Recent Developments
5.10 Danaher
5.10.1 Danaher Profile
5.10.2 Danaher Main Business
5.10.3 Danaher Companion Diagnostic Products, Services and Solutions
5.10.4 Danaher Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.10.5 Danaher Recent Developments
5.11 Illumina, Inc
5.11.1 Illumina, Inc Profile
5.11.2 Illumina, Inc Main Business
5.11.3 Illumina, Inc Companion Diagnostic Products, Services and Solutions
5.11.4 Illumina, Inc Companion Diagnostic Revenue (US$ Million) & (2018-2023)
5.11.5 Illumina, Inc Recent Developments
6 North America
6.1 North America Companion Diagnostic Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Companion Diagnostic Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Companion Diagnostic Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Companion Diagnostic Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Companion Diagnostic Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Companion Diagnostic Market Dynamics
11.1 Companion Diagnostic Industry Trends
11.2 Companion Diagnostic Market Drivers
11.3 Companion Diagnostic Market Challenges
11.4 Companion Diagnostic Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
